International Flavors & Fragrances Inc. (IFF) is scheduled to report first-quarter 2024 results on May 6, after the closing bell.Q4 PerformanceIn the last reported quarter, IFF’s earnings and revenues declined on a year-over-year basis. The company missed the Zacks Consensus Estimate for the top and bottom lines.International Flavors has surpassed earnings estimates in one of the trailing four quarters and missed in the other three, the average negative surprise being 2.7%.Q1 EstimatesThe Zacks Consensus Es ...

Wall Street analysts forecast that International Flavors (IFF) will report quarterly earnings of $0.84 per share in its upcoming release, pointing to a year-over-year decline of 3.5%. It is anticipated that revenues will amount to $2.81 billion, exhibiting a decline of 7.3% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reas ...

Wall Street expects a year-over-year decline in earnings on lower revenues when International Flavors (IFF) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 6, 2024, might help the stock move higher if these key numbers are better than e ...

International Flavors & Fragrances (IFF) revealed that it completed the previously announced sale of its Cosmetic Ingredients business to Clariant. The Cosmetic Ingredients unit includes the Lucas Meyers Cosmetics and IBR brands and operates six research and development, and production sites globally.This marks another step in the company’s ongoing efforts to optimize and streamline its portfolio to drive simplification and growth.  In December 2022, the company announced a new strategic and financial visio ...

International Flavors & Fragrances (IFF) has announced that it has entered into an agreement to sell its Pharma Solutions business to Roquette for an enterprise value of up to $2.85 billion.France-based Roquette specializes in plant-based ingredients. IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business, which supports industrial and methyl cellulosic food applications.The unit operates 10 research ...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) today announced that it has entered into a definitive agreement to sell its Pharma Solutions business unit to French leader of plant-based ingredients Roquette for an enterprise value of up to $2.85 billion, which represents an enterprise value to EBITDA multiple of approximately 13x. IFF’s Pharma Solutions business is a well-established developer and manufacturer of pharmaceutical excipients and includes its Global Specialty Solutions business supporting industria ...

文章核心观点 - 公司宣布授予新任CEO J. Erik Fyrwald股权激励奖励,作为其加入公司的重要诱因[1][2][3][4][5] - 该激励奖励包括68,750份绩效股票单位(最高可达171,875份)和56,250份限制性股票单位,总计最高228,125股[3] - 绩效股票单位的业绩指标包括股息调整后的收盘价、3年绝对及相对总股东回报率[3] - 该激励奖励将在一定情况下加速或持续性解锁,如员工离职或公司发生特定交易[4] - 该激励奖励是在公司股东批准的股权激励计划之外授予的,但将遵循公司2021年股票奖励和激励计划的相同条款[5] 公司信息 - 国际香料与香精公司(IFF)是一家领先的食品、饮料、健康、生物科学和香料行业公司[7] - 公司致力于通过科学和创意为客户提供关键解决方案,从全球知名品牌到意想不到的创新和体验[7] - 公司在全球拥有员工,并在纽约证券交易所上市(股票代码:IFF)[7] 行业信息 - 公司所处的食品、饮料、健康、生物科学和香料行业是一个重要的全球性行业[7] - 该行业需要结合艺术的美感和科学的精确性,与客户合作开发受消费者青睐的产品[7]

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF)—a world leader in food and beverage, home and personal care, and health—has been named the top American Company for gender equality and tenth globally by Equileap, a leading organization providing data and insights on gender equality in the corporate sector. In its seventh annual Gender Equality Global Report & Ranking, Equileap provides a status update on gender equality in the corporate world, evaluating 19 different criteria that range from the gender pay gap ...

销售情况 - 2023年销售额为114.79亿美元，较2022年下降8%[107] - Nourish部门2023年销售额为60.6亿美元，较2022年下降11%[112] - 2023年销售额25大客户占比约为32%[108] - 2023年俄罗斯客户销售额占比约为1%[103] - 2023年乌克兰客户销售额占比小于1%[103] - 2023年销售额货币中性基础下减少6%[111] - 2023年健康与生物科学销售额为20.81亿美元，同比下降11%[113] - 2023年香水销售额为23.93亿美元，同比增长4%[114] - 2023年医药解决方案销售额为9.45亿美元，同比下降3%[116] 财务状况 - 2023年净利润为-25.67亿美元，较2022年下降37%[110] - 2023年毛利率为32.1%，较2022年下降130个基点[110] - 2023年研发费用占销售额的比例为5.5%，较2022年增加70个基点[110] - 2023年销售成本为77.98亿美元，占销售额的67.9%[117] - 2023年研发费用为6.36亿美元，占销售额的5.5%[118] - 2023年销售和管理费用为17.87亿美元，占销售额的15.6%[119] - 2023年重组及其他费用为6.8亿美元，较2022年增加56百万美元[121] - 公司于2023年12月31日的净债务与信贷调整后EBITDA比率为4.51比1.0[144] - 公司于2023年12月31日的总债务为100.96亿美元，净债务为93.67亿美元[146] 资金情况 - 2023年净利润为负25.18亿美元，较2022年下降893百万美元[129] - 2023年现金及现金等价物为7.29亿美元，较2022年增加19.4亿美元[135] - 2023年，公司的融资活动中使用的现金流为18.51亿美元，较2022年的12.29亿美元和2021年的13.04亿美元有所增加[138] - 2023年，公司支付的股息总额为8.26亿美元，较2022年的8.10亿美元和2021年的6.67亿美元有所增加[139] 债务和资产 - 公司于2021年2月与营养与生物科学公司进行了交易，涉及12.5亿美元的无担保期限贷款信贷额度和73.59亿美元的特别现金支付[141] - 公司于2023年12月31日符合所有信贷协议中的财务和其他契约[144] - 公司于2023年12月31日持有908.5亿美元的养老金资金义务和3.8亿美元的离退休义务[156] - 公司于2023年12月31日有大约3.965亿美元的未来利息支付与债务相关，其中大约2.92亿美元在12个月内到期[154] 风险管理 - 公司在收购业务时，根据GAAP标准将购买考虑支付给资产和负债，超出购买价格的部分记录为商誉[160] - 公司通常使用第三方估值专家协助估算重要有形和无形资产的公允价值[161] - 公司于2023年12月31日拥有约106.35亿美元的商誉，每年11月30日对商誉进行减值测试[162] - 公司因俄罗斯和乌克兰业务不确定性，于2022年录得约1.2亿美元的长期资产减值损失[164] - 公司使用非GAAP财务指标，包括货币中性指标和调整后的营业EBITDA和营业EBITDA利润率[166] - 公司提醒投资者注意前瞻性声明，应考虑公司业务中存在的许多风险和不确定性[168] - 公司的实际结果可能会与前瞻性声明中的预期结果有所不同，风险包括债务影响、战略转型执行、法律索赔、通货膨胀等[169] - 公司需要考虑多种因素，如供应链中断、地缘政治事件、数据泄露等对业务的影响[170] - 公司在2023年12月31日的外汇风险敏感性分析显示，外汇远期合约的估计公允价值将因美元汇率的10%下降或上升而变化约为1.53亿美元[173] - 公司使用利率互换协议来管理欧洲投资的外汇风险，截至2023年12月31日，这些互换协议处于负债位置，总公允价值为1.61亿美元[173] - 公司在2023年12月31日的欧元固定利率债务的公允价值为13.84亿美元，若外汇汇率下降或上升10%，其估计公允价值将变化约为1.43亿美元[173]

International Flavors & Fragrances Inc. (NYSE:IFF) Q4 2023 Earnings Conference Call February 21, 2024 9:00 AM ET Company Participants Michael DeVeau - Senior Vice President, Corporate Finance & Investor Relations Erik Fyrwald - Chief Executive Officer Glenn Richter - Executive Vice President, Chief Financial & Business Transformation Officer Conference Call Participants Ghansham Panjabi - Baird Josh Spector - UBS Gunther Zechmann - Alliance Bernstein David Begleiter - Deutsche Bank Lisa De Neve - Morgan Sta ...